GPRC5D and plasma cell myeloma: To enhance the antimyeloma efficacy of CAR T-cell therapy and prevent myeloma cells from evading treatment through antigen loss and downregulation, dual-antigen targeting of BCMA and other myeloma antigens such as SLAMF7, CD19, and GPRC5D has been proposed [127, 128].